Αποτελέσματα Αναζήτησης
11 Νοε 2021 · A combination consisting of the ICI atezolizumab and the anti-angiogenic agent bevacizumab is the first treatment regimen that has been shown to improve overall survival in patients with...
29 Φεβ 2024 · Asymptomatic patients with a low tumour burden and good liver function (Barcelona Clinic Liver Cancer stage (BCLC) 0) should undergo local curative treatments, such as resection or local...
17 Ιουλ 2020 · Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Article 28 January 2021. Introduction. The treatment of liver cancer has benefited...
Κυριότερες Ειδήσεις
There are currently six FDA-approved immunotherapy options for liver cancer. Immunomodulators. Atezolizumab (Tecentriq®): a checkpoint inhibitor that targets the PD-L1 pathway; approved, in combination with bevacizumab, as a first-line treatment for subsets of patients with advanced liver cancer
27 Δεκ 2019 · The only treatment with curative intent and offering the longest survivals for these primary liver malignancies is surgery (liver transplantation, surgical resection or radiofrequency ablation for HCCs; surgical resection for BTCs), but it is restricted to a minority of patients with localized diseases.
25 Ιαν 2023 · Immunotherapy is thought to induce severe graft rejection in transplant recipients due to the activation of the innate immune response [71, 74]. This can be mitigated by an adequate washout period, modalities such as plasmapheresis, as well as increased immunosuppression post-transplant.
